# Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

> **NCT03152591** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 29 (actual)

## Conditions studied

- Polycystic Ovary Syndrome

## Interventions

- **DRUG:** LIK066
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03152591
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-24
- **Primary completion:** 2018-06-25
- **Final completion:** 2018-06-25
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03152591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03152591, "Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03152591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*